{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T12:08:59Z","timestamp":1747224539787,"version":"3.40.5"},"reference-count":12,"publisher":"PAGEPress Publications","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Monaldi Arch Chest Dis"],"abstract":"<jats:p>Covid-19 in immunocompromised patients shows a prolonged course and may lead to a poor prognosis. Although data on hyperimmune plasma for treatment of Covid-19 suggest an improved outcome in immunocompetent patients, limited data are currently available in immunocompromised patients. We present the case of a 62-year-old Caucasian woman, who was previously treated with obinutuzumab and bendamustine for follicular lymphoma and showed a prolonged positive test for Covid-19. Since no improvement was observed with standard of care (including remdesivir), the possibility of hyperimmune plasma infusion was discussed. A first dose of hyperimmune plasma was administered, with subsequent onset of fever, increasing inflammatory indexes and worsening radiological findings. Three days later a second dose of plasma was administered. Within twelve hours cough and fever disappeared, and oxygen at rest was discontinued. The patient was discharged 5 days later, and nasopharyngeal swabs resulted negative 16 days after discharge.<\/jats:p>","DOI":"10.4081\/monaldi.2021.1867","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T06:30:36Z","timestamp":1623393036000},"source":"Crossref","is-referenced-by-count":5,"title":["Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma"],"prefix":"10.4081","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7163-2270","authenticated-orcid":false,"given":"Guido","family":"Levi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Rocchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1667-2277","authenticated-orcid":false,"given":"Roberto","family":"Magri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Uccelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damiano","family":"Bottone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Quadri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Novali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Bezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2549","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"6026","doi-asserted-by":"crossref","unstructured":"Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-3.","DOI":"10.1056\/NEJMoa2001017"},{"key":"6027","doi-asserted-by":"crossref","unstructured":"Karata\u015f A, \u0130nkaya A\u00c7, Demiro\u011flu H, et al. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma. Transfus Apher Sci 2020;59:102871.","DOI":"10.1016\/j.transci.2020.102871"},{"key":"6028","doi-asserted-by":"crossref","unstructured":"Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. Cancer Discov 2020;10:783-91.","DOI":"10.1158\/2159-8290.CD-20-0422"},{"key":"6029","doi-asserted-by":"crossref","unstructured":"Malsy J, Veletzky L, Heide J, et al. Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19. Clin Infect Dis 2020:ciaa1637. Online ahead of print.","DOI":"10.1093\/cid\/ciaa1637"},{"key":"6030","doi-asserted-by":"crossref","unstructured":"Ferrari S, Caprioli C, Weber A, et al. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies. Leuk Lymphoma 2021;62:1490-6.","DOI":"10.1080\/10428194.2021.1872070"},{"key":"6031","doi-asserted-by":"crossref","unstructured":"Shah V, Ko Ko T, Zuckerman M, et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with hematological malignancies; King\u2019s College Hospital experience. Br J Haematol 2020;190:e279-282.","DOI":"10.1111\/bjh.16935"},{"key":"6032","doi-asserted-by":"crossref","unstructured":"Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med 2020;383:2291-3.","DOI":"10.1056\/NEJMc2031364"},{"key":"6033","doi-asserted-by":"crossref","unstructured":"Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - Final Report. N Engl J Med 2020;383:1813-26.","DOI":"10.1056\/NEJMc2022236"},{"key":"6034","doi-asserted-by":"crossref","unstructured":"Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020;117:9490\u20136.","DOI":"10.1073\/pnas.2006961117"},{"key":"6035","doi-asserted-by":"crossref","unstructured":"Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020;323:1582-9.","DOI":"10.1001\/jama.2020.4783"},{"key":"6036","doi-asserted-by":"crossref","unstructured":"Libster R, P\u00e9rez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med 2021;384:610-8.","DOI":"10.1056\/NEJMoa2033700"},{"key":"6037","doi-asserted-by":"crossref","unstructured":"Wright Z, Bersabe A, Eden R, et al. Successful use of COVID-19 convalescent plasma in a patient recently treated for follicular lymphoma. Clin Lymphoma Myeloma Leuk 2021;21:66-8.","DOI":"10.1016\/j.clml.2020.06.012"}],"container-title":["Monaldi Archives for Chest Disease"],"original-title":[],"link":[{"URL":"https:\/\/monaldi-archives.org\/index.php\/macd\/article\/download\/1867\/1276","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/monaldi-archives.org\/index.php\/macd\/article\/download\/1867\/1276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T06:31:38Z","timestamp":1623393098000},"score":1,"resource":{"primary":{"URL":"https:\/\/monaldi-archives.org\/index.php\/macd\/article\/view\/1867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":12,"URL":"https:\/\/doi.org\/10.4081\/monaldi.2021.1867","relation":{},"ISSN":["2532-5264","1122-0643"],"issn-type":[{"type":"electronic","value":"2532-5264"},{"type":"print","value":"1122-0643"}],"subject":[],"published":{"date-parts":[[2021,6,10]]}}}